Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival-Reference-Cited by-同舟云学术

Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival

Published:2005-02-15 Issue:4 Volume:105 Page:1759-1767
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Kim Kyu-Tae¹,Baird Kristin¹,Ahn Joon-Young¹,Meltzer Paul¹,Lilly Michael¹,Levis Mark¹,Small Donald¹

Affiliation:

1. From the Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD; the Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD; the Cancer Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD; and the Department of Medicine, Loma Linda University School of Medicine, Loma Linda, CA.

Abstract

AbstractConstitutively activating internal tandem duplication (ITD) mutations of the receptor tyrosine kinase FLT3 (Fms-like tyrosine kinase 3) play an important role in leukemogenesis, and their presence is associated with poor prognosis in acute myeloid leukemia (AML). To better understand FLT3 signaling in leukemogenesis, we have examined the changes in gene expression induced by FLT3/ITD or constitutively activated wild-type FLT3 expression. Microarrays were used with RNA harvested before and after inhibition of FLT3 signaling. Pim-1 was found to be one of the most significantly down-regulated genes upon FLT3 inhibition. Pim-1 is a proto-oncogene and is known to be up-regulated by signal transducer and activator of transcription 5 (STAT5), which itself is a downstream target of FLT3 signaling. Quantitative polymerase chain reaction (QPCR) confirmed the microarray results and demonstrated approximately 10-fold decreases in Pim-1 expression in response to FLT3 inhibition. Pim-1 protein also decreased rapidly in parallel with decreasing autophosphorylation activity of FLT3. Enforced expression of either the 44-kDa or 33-kDa Pim-1 isotypes resulted in increased resistance to FLT3 inhibition-mediated cytotoxicity and apoptosis. In contrast, expression of a dominant-negative Pim-1 construct accelerated cytotoxicity in response to FLT3 inhibition and inhibited colony growth of FLT3/ITD-transformed BaF3 cells. These findings demonstrate that constitutively activated FLT3 signaling up-regulates Pim-1 expression in leukemia cells. This up-regulation contributes to the proliferative and antiapoptotic pathways induced by FLT3 signaling. (Blood. 2005;105: 1759-1767)

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/105/4/1759/1707017/zh800405001759.pdf

Reference54 articles.

1. Rosnet O, Birnbaum D. Hematopoietic receptors of class III receptor-type tyrosine kinases. Crit Rev Oncog.1993;4: 595-613.

2. DaSilva N, Hu ZB, Ma W, Rosnet O, Birnbaum D, Drexler HG. Expression of the FLT3 gene in human leukemia-lymphoma cell lines. Leukemia.1994;8: 885-888.

3. Carow CE, Levenstein M, Kaufmann SH, et al. Expression of the hematopoietic growth factor receptor FLT3 (STK-1/Flk2) in human leukemias. Blood.1996;87: 1089-1096.

4. Birg F, Courcoul M, Rosnet O, et al. Expression of the FMS/KIT-like gene FLT3 in human acute leukemias of the myeloid and lymphoid lineages. Blood.1992;80: 2584-2593.

5. Nakao M, Yokota S, Iwai T, et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia.1996;10: 1911-1918.

Cited by 191 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identifying Suitable Reference Gene Candidates for Quantification of DNA Damage-Induced Cellular Responses in Human U2OS Cell Culture System;Biomolecules;2023-10-13

2. Identification of cellular senescence-related signature for predicting prognosis and therapeutic response of acute myeloid leukemia;Aging;2023-10-13

3. Phase 1/2 Study of the Pan-PIM Kinase Inhibitor INCB053914 Alone or in Combination With Standard-of-Care Agents in Patients With Advanced Hematologic Malignancies;Clinical Lymphoma Myeloma and Leukemia;2023-09

4. Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML;Clinical Cancer Research;2023-05-24

5. Design, synthesis and cytotoxic evaluation of novel bis-thiazole derivatives as preferential Pim1 kinase inhibitors with in vivo and in silico study;Journal of Enzyme Inhibition and Medicinal Chemistry;2023-02-02